People Want an Alzheimer’s Drug. Aducanumab Isn’t the One. May 28, 2021 Auto Bot alzheimer's disease, Brain, Clinical Trials, Placebos 0 An F.D.A. sign-off for aducanumab would make finding a good treatment harder.